Active Surveillance of Papillary Thyroid Microcarcinoma
ConditionPapillary Thyroid Microcarcinoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCedars-Sinai Medical Center
About this trial
The purpose of this study is to better understand the outcomes of active surveillance (observation) instead of immediate surgery, which is the current standard of care for papillary thyroid microcarcinoma (PTMC). Patients with a 1.5 cm or smaller thyroid nodule(s) with papillary thyroid carcinoma will be eligible for the study.
Eligibility criteria
Qualifiers
Pathologically confirmed Bethesda V or VI thyroid nodules with papillary thyroid carcinoma or high clinical suspicion, or pathologically confirmed Bethesda III or IV nodules with BRAF mutation.
2.0 cm or smaller nodules by ultrasonographic criteria
Ability to understand and the willingness to sign a written informed consent and HIPAA Authorization form
Must be able to read and write English fluently to participate in the questionnaire portion of the study
Disqualifiers
High-grade or poorly differentiated PTC variants
Central or lateral neck lymphadenopathy suspicious for PTC
Unfavorable nodule location (e.g. Near dorsal surface (by recurrent laryngeal nerve); Adjacent to trachea (risk of cartilage invasion)
History of radiation to neck
Trial design
Treatments tested in this trial
- Active Surveillance
Treatment groups
216 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov